VF
RXRX icon

Virtu Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Virtu Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-149,722
Closed -$460K – 2157
2026
Q1 		$460K Buy
+149,722
New +$579K 0.02% 605
2025
Q3 		– Sell
-449,092
Closed -$2.27M – 2003
2025
Q2 		$2.27M Buy
449,092
+415,056
+1,219% +$2.04M 0.12% 146
2025
Q1 		$180K Buy
+34,036
New +$248K 0.01% 837
2024
Q4 		– Sell
-37,512
Closed -$247K – 1989
2024
Q3 		$247K Sell
37,512
-17,014
-31% -$122K 0.01% 713
2024
Q2 		$409K Sell
54,526
-11,915
-18% -$104K 0.03% 498
2024
Q1 		$662K Buy
+66,441
New +$740K 0.05% 333
2023
Q3 		– Sell
-27,205
Closed -$203K – 1812
2023
Q2 		$203K Buy
+27,205
New +$190K 0.02% 809

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial's RXRX Position: Q2 2026 in Review

Virtu Financial sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 149,722 shares — an estimated $460K sold.

Virtu Financial first reported a position in RXRX in Q2 2023 and held it in 7 quarters. The position peaked at $2.27M in Q2 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Virtu Financial reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 149,722 Recursion Pharmaceuticals shares in Q2 2026, an estimated $460K.
  • Virtu Financial first reported a position in Recursion Pharmaceuticals in Q2 2023 and held it in 7 quarters.
  • Virtu Financial's Recursion Pharmaceuticals position peaked at $2.27M in Q2 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.